Anales de la RANM

240 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 ACTUALIZACIÓN DE ANTICOAGULACIÓN EN FIBRILACIÓN ARTICULAR Antoñana Ugalde S, et al. An RANM. 2024;141(03): 232 - 2 40 sociated atrial fibrillation. New Engl J Med. 2022;387(11): 978-988. 28. Joosten LPT, Van Doorn S, Van De Ven PM et al. Safety of switching from a vitamin K anta- gonist to a non-vitamin K antagonist oral an- ticoagulant in frail older patients with atrial fibrillation: Results of the FRAIL-AF randomi- zed controlled trial. Circulation. 2024; 149(4): 279-289. 29. Nelson WW, Laliberté F, Patel AA et al. Stroke risk reduction outweighed bleeding risk increa- se from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. Curr Med Res Opin. 2017; 33(4): 631-638. 30. Paciaroni M, Agnelli G, Caso V et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention: The RENo Study. Stroke. 2019; 50(8): 2168-2174. 31. Reddy VY, Doshi SK, Kar S et al. 5-year outco- mes after left atrial appendage closure from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017; 70(24): 2964-2975. 32. Whitlock RP, Belley-Cote EP, Paparella D et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. New Engl J Med. 2021; 384(22): 2081-2091. 33. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017; 28(7): 2241-2248. 34. De Vriese AS, Caluwé R, Bailleul E et al. Dose- finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis. 2015; 66(1): 91-98. 35. Reinecke H, Engelbertz C, Bauersachs R et al. A randomized controlled trial comparing apixa- ban with the vitamin K antagonist phenprocou- mon in patients on chronic hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 2023; 147(4): 296-309. 36. Pokorney SD, Chertow GM, Al-Khalidi HR et al. Apixaban for patients with atrial fibrilla- tion on hemodialysis: a multicenter randomi- zed controlled trial. Circulation. 2022; 146(23): 1735-1745. 37. de Vriese AS, Caluwé R, van der Meersch H, de Boeck K, de Bacquer D. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021; 32(6):1474-1483. 38. Faisaluddin M, Alwifati N, Naeem et al. Safety and efficacy of direct oral anticoagulants ver- sus warfarin for atrial fibrillation in end-stage renal disease on hemodialysis: a meta-analysis of randomized control trials. Am J Cardiol. 2023; 206: 309-311. 39. Pollak WM, Simmons JD, Interian A et al. Cli- nical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol. 2001; 24(4Pt1): 424-429. 40. Healey JS, Connolly SJ, Gold MR et al. Subcli- nical Atrial Fibrillation and the Risk of Stroke. N Engl J Med. 2012; 366(2): 120-129. 41. Kirchhof P, Toennis T, Goette A et al. Anticoa- gulation with edoxaban in patients with atrial high-rate episodes. New Engl J Med. 2023; 389(13) :1167-1179. 42. Link MS, Giugliano RP, Ruff CT et al. Stroke and mortality risk in patients with various patterns of atrial fibrillation: Results from the ENGAGE AF-TIMI 48 Trial (Effective anticoa- gulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarc- tion 48). Circ Arrhythm Electrophysiol. 2017; 10(1): e004267. 43. Vanassche T, Lauw M, Eikelbook JW et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: Analysis of 6563 aspirin- treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015; 36(5): 281-288. 44. Healey JS, Lopes RD, Granger C et al. Apixaban for Stroke Prevention in Subclinical Atrial Fi- brillation. New Engl J Med. 2024; 390(2): 107- 117. 45. Becher N, Toennis T, Bertaglia E et al. Anticoa- gulation with edoxaban in patients with long atrial high-rate episodes ≥24 h. Eur Heart J. 2024; 45(10): 837-849. Si desea citar nuestro artículo: Antoñana Ugalde S, Moreno Planas J, Zamorano Gómez JL. Actua- lización de anticoagulación en fibrilación auricular. An RANM. 2024;141(03): 2 32–240. DOI: 10.32440/ar.2024.141.03. rev04